Selank — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Selank

Also known as: Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tuftsin analogue, Selanque, TP-7 (glyproline heptapeptide), Selank heptapeptide

Synthetic heptapeptide anxiolytic / nootropic / immunomodulator (glyproline family, tuftsin analogue)

Research chemicalLast updated: October 31, 2026Based on 27 peer-reviewed studies

What it is

Selank is a synthetic peptide used in Russia as a prescription anxiolytic, and in the nootropics community worldwide for anxiety relief and cognitive support. It works by modulating the brain's opioid and neurotransmitter systems to reduce stress and improve focus. Approved in Russia for anxiety disorders; not FDA-approved; regulatory status varies by country.

The scientific side

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the endogenous immunopeptide tuftsin. Multiple mechanisms have been proposed in the reviewed literature: (1) Inhibition of enkephalin-degrading enzymes (enkephalinases) in human plasma, thereby prolonging the half-life of endogenous leu-enkephalin — this is suggested as a primary anxiolytic mechanism (PMIDs: 11550013, 32342318, 29181670, 15344652, 11443939). (2) Positive allosteric modulation of GABA-A receptors, with a modulatory site apparently distinct from but potentially overlapping with benzodiazepine and antipsychotic binding sites. (3) Upregulation of spontaneous inhibitory postsynaptic currents in hippocampal CA1 neurons. (4) Modulation of Th1/Th2 cytokine balance and immune function, including induction of IFN-α gene expression and suppression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, TGF-β1) under stress conditions (PMIDs: 19882898, 18577961, 32621722). (5) Enhancement of brain-derived neurotrophic factor (BDNF) regulation in the hippocampus and prefrontal cortex. (6) Anticoagulant activity demonstrated by thromboelastography. One review also mentions enhancement of BDNF and HGF/c-Met pathways critical to neuroplasticity. GABA receptor-related mechanism is noted in a pharmacology review.

Class: Synthetic heptapeptide anxiolytic / nootropic / immunomodulator (glyproline family, tuftsin analogue)

Modified Forms

The following chemical variants are structurally derived from this peptide. They are documented here rather than on separate pages.

N-Acetyl Selank Amidate

N-Acetyl Selank Amidate is structurally identical to Selank with N-terminal acetylation and C-terminal amidation added to resist peptidase cleavage. These modifications extend enzymatic stability relative to the parent sequence. No peer-reviewed studies specific to this modified form were identified in any literature search — all mechanism and safety assumptions are extrapolated from Selank data. Community users typically administer it intranasally at doses reported to be lower than standard Selank, though this dose adjustment is empirical and has no experimental basis in published research. Regulatory status mirrors Selank: unapproved in all reviewed jurisdictions.

How dosing differs: Community use typically mirrors Selank intranasal protocols (250–400 mcg) or slightly lower due to assumed stability advantage. No published dose-finding data exists for this modified form.

Key differences from parent: Same terminal modifications as N-Acetyl Semax Amidate applied to the Selank sequence: N-terminal acetylation and C-terminal amidation for enzymatic stability. No independent pharmacological studies distinguish this form from standard Selank.

Administration & storage

Administration
Intraperitoneal injection (animal studies; PMIDs: 3632230431625062326217223265182631236882312436792885310012432865)Intranasal administration (human clinical study; PMID: 18454096)Oral administration (human clinical study; PMID: 18454096)Intraperitoneal injection — preventive scheme in mice (antiviral studies; PMID: 19882898)
Storage
One abstract notes Selank is sold online as lyophilized powder for injection or in nasal spray formulations. No specific storage temperature, duration, or conditions are stated in any reviewed abstract.
Cautions
Selank is described as a 'poorly studied' drug with GABAergic mechanisms; significant evaluation of abuse potential, dependence, and withdrawal has not been adequately conducted prior to public access.,Selank has not completed clinical trials according to one reviewed abstract; it is characterized as a 'research peptide'.,Anticoagulant effects have been demonstrated in animal thromboelastography studies; potential bleeding risk in humans is unknown.,Selank modulates GABA-A receptor activity and cytokine balance; interactions with other GABAergic drugs (e.g., benzodiazepines, antipsychotics) have been observed in vitro and in vivo — combined use may produce unpredictable effects (PMIDs: 30255741, 28293190, 28280289).,Sterile technique is essential when handling any injectable preparation to prevent contamination.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification. One reviewed abstract characterizes Selank as a 'poorly studied Russian drug' sold to US consumers 'inexplicably as a dietary supplement,' and notes it…

WADA

Not stated in reviewed literature — requires manual verification.

Health Canada

Not stated in reviewed literature — requires manual verification.